Elesclomol

Overview

Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal additional toxicity, at moderate doses. It is being developed by Synta Pharmaceuticals.

Indication

Investigated for use/treatment in melanoma.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Statins, Cholesterol and Cognitive Decline in Alzheimer's	2024/10/10	NCT06635252	N/A	Completed	Karolinska Institutet
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia	2011/01/21	NCT01280786	Phase 1	UNKNOWN	Synta Pharmaceuticals Corp.
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	2009/04/27	NCT00888615	Phase 2	Completed	GOG Foundation
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors	2009/01/22	NCT00827203	Phase 1	Suspended	Synta Pharmaceuticals Corp.
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer	2008/12/15	NCT00808418	Phase 1	Completed	Synta Pharmaceuticals Corp.
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma	2007/08/30	NCT00522834	Phase 3	Terminated	Synta Pharmaceuticals Corp.
A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas	2004/07/23	NCT00087997	Phase 2	Completed	Synta Pharmaceuticals Corp.
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)	2004/07/21	NCT00088088	Phase 1	Completed	Synta Pharmaceuticals Corp.
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma	2004/06/10	NCT00084214	Phase 1	Completed	Synta Pharmaceuticals Corp.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Non-Histone Lactylation Emerges as Key Regulator in Cancer Progression and Therapeutic Target

7 months ago

Non-histone lactylation, a novel post-translational modification, plays critical roles in cancer progression by modulating protein stability, enzyme activity, and cellular signaling pathways beyond traditional histone modifications.

Immune-Based AML Subgroups Reveal Prognostic and Therapeutic Implications

10 months ago

Researchers identified two immune-based subgroups in acute myeloid leukemia (AML), G1 and G2, with distinct immune infiltration and mutational profiles.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access